文献速递心脑血管急症

生物自适应植入物与当代药物洗脱支架在瑞典经皮冠状动脉介入治疗中的比较(INFINITY-SWEDEHEART):一项单盲、非劣效性、基于注册的随机对照试验

Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.
PubMed 文献 · Lancet · 2024-10-28
一句话结论在瑞典20家医院PCI患者中,生物自适应植入物12个月靶病变失败非劣效于当代DES,6个月后事件率更低。

INFINITY-SWEDEHEART是一项在瑞典20家医院开展的单盲、非劣效性、基于注册的随机对照试验,纳入2399例18-85岁慢性或急性冠脉综合征、有PCI指征且最多三处原发病变适合单器械植入并预扩张成功的患者。患者1:1随机接受DynamX生物自适应植入物或佐他莫司洗脱DES(Resolute Onyx和Onyx Trustar)。主要终点12个月靶病变失败在生物自适应组28/1189(2.4%)vs DES组33/1192(2.8%),风险差-0.41%(95%CI -1.94至1.11;p非劣效<0.0001),达到非劣效。预设6-12个月界标分析中,生物自适应组靶病变失败0.3%(3/1170)vs DES组1.7%(16/1176)(HR 0.19,95%CI 0.06-0.65;p=0.0079)。作者认为生物自适应植入物有潜力减少非平台期器械相关事件并改善PCI患者结局。

要点

  • 12个月靶病变失败:生物自适应组28/1189(2.4%)vs DES组33/1192(2.8%),风险差-0.41%(95%CI -1.94至1.11),非劣效成立(p非劣效<0.0001)。
  • 6-12个月界标分析靶病变失败:生物自适应组0.3%(3/1170)vs DES组1.7%(16/1176),HR 0.19(95%CI 0.06-0.65;p=0.0079)。
  • 6-12个月靶血管失败:生物自适应组0.8%(8/1167)vs DES组2.5%(23/1174),HR 0.35(95%CI 0.16-0.79;p=0.011)。
  • 急性冠脉综合征患者6-12个月靶病变失败:生物自适应组0.3%(2/906)vs DES组1.8%(12/895),HR 0.17(95%CI 0.04-0.74;p=0.018)。
  • 明确或 probable 器械血栓安全终点低且组间无差异:生物自适应组8/1201(0.7%)vs DES组6/1198(0.5%),事件率差0.16%(95%CI -0.50至0.83)。

适用人群与场景

  • 年龄18-85岁,慢性或急性冠脉综合征缺血性心脏病,有PCI指征,最多三处原发病变适合每处病变植入单个器械,且预扩张成功,通过瑞典冠状动脉造影和血管成形术注册登记筛选合格。

诊断标准与关键阈值

  • 非劣效界值:绝对风险差的两侧95%CI上限小于4.2%。
  • 主要终点靶病变失败定义为心血管死亡、靶血管心肌梗死和缺血驱动的靶病变血运重建的复合终点。
  • 靶血管失败定义为心血管死亡、靶血管心肌梗死和缺血驱动的靶血管血运重建的复合终点。

处置流程与药物剂量

  • 随机1:1接受DynamX生物自适应植入物(Elixir Medical, Milpitas, CA, USA)或佐他莫司洗脱DES(Resolute Onyx和Onyx Trustar, Medtronic, Minneapolis, MN, USA),每处病变植入单个器械,预扩张成功。
  • 随访至5年正在进行中。

研究设计与关键结果

  • 研究类型:单盲、非劣效性、基于注册的随机对照试验,在瑞典20家医院开展,2399例患者随机(生物自适应组n=1201,DES组n=1198;ITT人群)。
  • 中位年龄69.5岁(IQR 61.2-75.6),女性575/2399(24.0%),男性1824/2399(76.0%),未收集种族和民族数据;急性冠脉综合征1838/2399(76.6%)。
  • 主要终点12个月靶病变失败:生物自适应组28/1189(2.4%)vs DES组33/1192(2.8%),风险差-0.41%(95%CI -1.94至1.11;p非劣效<0.0001)。
  • 6-12个月界标分析靶病变失败Kaplan-Meier估计:生物自适应组0.3%(3/1170)vs DES组1.7%(16/1176),HR 0.19(95%CI 0.06-0.65;p=0.0079)。
  • 6-12个月界标分析靶血管失败:生物自适应组0.8%(8/1167)vs DES组2.5%(23/1174),HR 0.35(95%CI 0.16-0.79;p=0.011)。
  • 6-12个月界标分析急性冠脉综合征患者靶病变失败:生物自适应组0.3%(2/906)vs DES组1.8%(12/895),HR 0.17(95%CI 0.04-0.74;p=0.018)。
  • 明确或 probable 器械血栓:生物自适应组8/1201(0.7%)vs DES组6/1198(0.5%),事件率差0.16%(95%CI -0.50至0.83)。

证据类型、等级与局限

  • 证据类型:单盲、非劣效性、基于注册的随机对照试验。
  • 研究由Elixir Medical资助。
  • 局限:原文报告后续计划随访将有助于强化1年发现的临床意义。

对床旁实践的改变

  • 在适合单器械植入且预扩张成功的PCI患者(包括急性冠脉综合征)中,生物自适应植入物12个月靶病变失败非劣效于当代DES。
  • 6个月后界标分析中生物自适应组靶病变失败、靶血管失败及急性冠脉综合征患者靶病变失败事件率更低,作者认为生物自适应植入物有潜力减少非平台期器械相关事件并改善PCI患者结局。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Persistent non-plateauing adverse event rates in patients who underwent percutaneous coronary intervention (PCI) remain a challenge. A bioadaptor is a novel implant that addresses this issue by restoring the haemodynamic modulation of the artery, allowing cyclic pulsatility, vasomotion, and adaptative remodelling, by unlocking and providing dynamic support to the artery. We aimed to assess outcomes with the device versus a contemporary drug-eluting stent (DES) in a representative PCI population.

METHODS: INFINITY-SWEDEHEART is a single-blind, non-inferiority, registry-based, randomised controlled study conducted in 20 hospitals in Sweden. Patients aged 18-85 years, with chronic or acute coronary syndrome ischaemic heart disease, with an indication for PCI, with up to three de novo lesions suitable for implantation with one single device per lesion, and successful pre-dilatation were identified via the Swedish Coronary Angiography and Angioplasty Registry and eligible for enrolment. Participants were randomly assigned (1:1), using block randomisation with random variation in block size and stratified by site, to either the DynamX bioadaptor (Elixir Medical, Milpitas, CA, USA) or a zotarolimus-eluting DES (Resolute Onyx and Onyx Trustar, Medtronic, Minneapolis, MN, USA). The primary endpoint was the device-oriented clinical endpoint of target lesion failure at 12 months (a composite of cardiovascular death, target vessel myocardial infarction, and ischaemia-driven target lesion revascularisation), assessed in the intention-to-treat (ITT) population (ie, all patients randomly assigned to treatment, regardless of treatment received) who had either experienced an event up to 12 months or completed the trial up to 12 months. Non-inferiority was established if the upper limit of the two-sided 95% CI for the absolute risk difference was less than 4·2%. Powered secondary endpoints were landmark analyses from 6 months onwards for target lesion failure, target vessel failure (composite of cardiovascular death, target vessel myocardial infarction, and ischaemia-driven target vessel revascularisation), and target lesion failure for patients with acute coronary syndrome assessed in the ITT population). This study is registered with ClinicalTrials.gov, NCT04562805, and follow-up to 5 years is ongoing.

FINDINGS: Between Sept 30, 2020, and July 11, 2023, 2399 patients were randomly assigned to receive the bioadaptor (n=1201) or DES (n=1198; ITT population). Median age was 69·5 years (IQR 61·2-75·6), 575 (24·0%) of 2399 patients were female, and 1824 (76·0%) were male (data on race and ethnicity were not collected), and 1838 (76·6%) patients presented with acute coronary syndrome. The primary endpoint of 12-month target lesion failure occurred in 28 (2·4%) of 1189 assessable patients in the bioadaptor group versus 33 (2·8%) of 1192 assessable patients in the DES group, with a risk difference of -0·41% (95% CI -1·94 to 1·11; pnon-inferiority<0·0001). In the prespecified landmark analysis from 6 months to 12 months, the Kaplan-Meier estimates of target lesion failure were 0·3% (with events in three of 1170 patients) in the bioadaptor group versus 1·7% (with events in 16 of 1176 patients) in the DES group (hazard ratio 0·19 [95% CI 0·06 to 0·65]; p=0·0079), of target vessel failure were 0·8% (events in eight of 1167) versus 2·5% (events in 23 of 1174; 0·35 [0·16 to 0·79]; p=0·011), and of target lesion failure in patients with acute coronary syndrome were 0·3% (events in two of 906) versus 1·8% (events in 12 of 895; 0·17 [0·04 to 0·74]; p=0·018). The rate of definite or probable device thrombosis, which was recorded as a safety outcome, was low and did not differ between groups (eight [0·7%] of 1201 in the bioadaptor group vs six [0·5%] of 1198 in the DES group; difference in event rates of 0·16% [95% CI -0·50 to 0·83]).

INTERPRETATION: Among patients with coronary artery disease, including those with acute coronary syndrome, treatment with the bioadaptor was non-inferior to contemporary DES, showing potential to mitigate non-plateauing device-related events and improving outcomes in patients undergoing PCI. The additional planned follow-up will help to reinforce the clinical significance of the 1-year findings.

FUNDING: Elixir Medical.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Erlinge D, Andersson J, Fröbert O, et al. Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial. Lancet. 2024. PMID: 39481425. doi:10.1016/S0140-6736(24)02227-X

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。